One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Platinum Hall of Fame
doi : 10.1016/j.eururo.2023.02.005
Volume 83, Issue 4, April 2023, Pages e91-e101
Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification
George J. Netto a,*, Mahul B. Amin b,c , Eva M. Compe �rat d , Anthony J. Gill e,f,g,y, Arndt Hartmann h , Holger Moch i,y, Santosh Menon j , Maria R. Raspollini k , Mark A. Rubin l , John R. Srigley m,y, Puay Hoon Tan n,y, Satish K. Tickoo o , Toyonori Tsuzuki p,y, Samra Turajlic q , Ian Cree r,à , Daniel M. Berney
doi : 10.1016/j.eururo.2022.09.015
Volume 83, Issue 4, April 2023, Pages 301-303
Removing the Designation of Cancer from Grade Group 1 Disease Will Do More Good than Harm
Andrew J. Vickers a,*, Matthew R. Cooperberg b,c , Scott E. Eggener
doi : 10.1016/j.eururo.2022.10.001
Volume 83, Issue 4, April 2023, Pages 304-306
The Impact of a Statewide Active Surveillance Initiative: A Roadmap for Increasing Active Surveillance Utilization Nationwide
Randy A. Vince Jr. a,*,y, Yilun Sun b,y, Brandon Mahal c , Kevin Ginsburg d , Arvin George a , Michael Cher e , Brian Lane f , Richard Sarle g , Todd M. Morgan a , Daniel E. Spratt
doi : 10.1016/j.eururo.2022.05.028
Volume 83, Issue 4, April 2023, Pages 307-310
Active surveillance (AS) is recommended as a management option for men with favorable-risk (low risk and favorable intermediate risk) prostate cancer; however, national rates remain low.
Active Surveillance in Michigan: What Is Possible When Payers Partner with Physicians
Matthew R. Cooperberg
doi : 10.1016/j.eururo.2023.01.010
Volume 83, Issue 4, April 2023, Pages 311-312
Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer
Alberto Gil-Jimenez a,b,1 , Jeroen van Dorp a,1 , Alberto Contreras-Sanz c , Kristan van der Vos a , Daniel J. Vis a,b , Linde Braaf d , Annegien Broeks d , Ron Kerkhoven e , Kim E.M. van Kessel f , Marı �a Jose � Ribal g , Antonio Alcaraz g , Lodewyk F.A. Wessels a,b,h , Roland Seiler i,j , Jonathan L. Wright k , Lourdes Mengual g , Joost Boormans f , Bas W.G. van Rhijn l,m , Peter C. Black c , Michiel S. van der Heijden
doi : 10.1016/j.eururo.2022.07.023
Volume 83, Issue 4, April 2023, Pages 313-317
Predictive Biomarkers in Muscle Invasive Bladder Cancer: Are We There Yet?
Srikala S. Sridhar a,*, Scott A. North b , Normand Blais
doi : 10.1016/j.eururo.2022.09.003
Volume 83, Issue 4, April 2023, Pages 318-319
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma
Petros Grivas a,b,*, Evgeny Kopyltsov c , Po-Jung Su d , Francis X. Parnis e , Se Hoon Park f , Yoshiaki Yamamoto g , Peter C. Fong h , Christophe Tournigand i , Miguel A. Climent Duran j , Aristotelis Bamias k , Claudia Caserta l , Jane Chang m , Paul Cislo m , Alessandra di Pietro n , Jing Wang o , Thomas Powles
doi : 10.1016/j.eururo.2022.04.016
Volume 83, Issue 4, April 2023, Pages 320-328
In JAVELIN Bladder 100, avelumab first-line maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS; primary endpoint) versus BSC alone in patients with advanced urothelial carcinoma (aUC) without disease progression with first-line platinum-containing chemotherapy.
Time to Rethink Quality of Life Assessment in Patients with Urothelial Cancer in the Current Therapeutic Era?
Cristiane Decat Bergerot a , Shilpa Gupta b,*
doi : 10.1016/j.eururo.2022.06.007
Volume 83, Issue 4, April 2023, Pages 329-330
Climate-smart Actions in the Operating Theatre for Improving Sustainability Practices: A Systematic Review
Benjamin Pradere a,*, Richard Mallet b , Alexandre de La Taille c , Franck Bladou d , Denis Prunet e , Sarah Beurrier f , Florian Bardet g , Xavier Game h , Georges Fournier i , Eric Lechevallier j , Paul Meria k , Xavier Matillon l , Thomas Polguer m , Nadia Abid l , Bertrand De Graeve n , Diana Kassab o , Arnaud Mejean p , Vincent Misrai q , Ugo Pinar r , on behalf of the Sustainability Task Force of the French Association of Urology
doi : 10.1016/j.eururo.2022.01.027
Volume 83, Issue 4, April 2023, Pages 331-342
Surgical activity contributes to global warming though the production of greenhouse gases and consumption of resources. To date, no clinical practice guidelines have been made to promote and implement climate-smart actions.
A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer
Anna Plym a,b,c,*,y, Yiwen Zhang b,y, Konrad H. Stopsack b,d , Be �ne �dicte Delcoigne e , Fredrik Wiklund c , Christopher Haiman f , Stacey A. Kenfield g , Adam S. Kibel a , Edward Giovannucci h , Kathryn L. Penney b,i,y, Lorelei A. Mucci
doi : 10.1016/j.eururo.2022.05.008
Volume 83, Issue 4, April 2023, Pages 343-351
Prostate cancer is the most heritable cancer. There is a need to identify possible modifiable factors for men at an increased risk of prostate cancer due to genetic factors.
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1
Fred Saad a,*, Johann de Bono b , Philippe Barthe �le �my c , Tanya Dorff d , Niven Mehra e , Giorgio Scagliotti f , Adam Stirling g , Jean-Pascal Machiels h , Vincent Renard i , Marco Maruzzo j , Celestia S. Higano k , Howard Gurney l , Cynthia Healy m , Helen Bhattacharyya n , Bhakti Arondekar o , Alexander Niyazov p , Karim Fizazi
doi : 10.1016/j.eururo.2022.05.030
Volume 83, Issue 4, April 2023, Pages 352-360
Talazoparib has shown antitumor activity with a manageable safety profile in men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR)/homologous recombination repair (HRR) alterations.
Obturator Nerve Injury in Robotic Pelvic Surgery: Scenarios and Management Strategies
Anibal La Riva y, Aref S. Sayegh y, Laura C. Perez, Jaime Poncel, Luis G. Medina, Brittany Adamic, Ryan Powers, Giovanni E. Cacciamani, Monish Aron, Inderbir Gill, Rene Sotelo
doi : 10.1016/j.eururo.2022.12.034
Volume 83, Issue 4, April 2023, Pages 361-368
Obturator nerve injury (ONI) is an uncommon complication of pelvic surgery, usually reported in 0.2–5.7% of cases undergoing surgical treatment of urological and gynecological malignancies involving pelvic lymph node dissection (PLND).
Re: Association of Prostate-specific Antigen Screening Rates with Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities: Prostate cancer screening needs not only to be well meant but also well done
Peter Albers
doi : 10.1016/j.eururo.2022.12.003
Volume 83, Issue 4, April 2023, Pages 369-370
Re: Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only
Ola Bratt a,* Anssi Auvinen
doi : 10.1016/j.eururo.2022.12.029
Volume 83, Issue 4, April 2023, Pages 370-371
Re: Seven‐year Efficacy and Safety Outcomes of Bulkamid for the Treatment of Stress Urinary Incontinence
Gopal Badlani
doi : 10.1016/j.eururo.2022.12.032
Volume 83, Issue 4, April 2023, Pages 371-372
Re: Single-incision Mini-slings for Stress Urinary Incontinence in Women
Andrea Braga a,b,* Maurizio Serati
doi : 10.1016/j.eururo.2022.12.017
Volume 83, Issue 4, April 2023, Page 372
Re: CO2 Surgical Laser for Treatment of Stress Urinary Incontinence in Women: A Randomized Controlled Trial
Maurizio Serati a Andrea Braga
doi : 10.1016/j.eururo.2022.12.016
Volume 83, Issue 4, April 2023, Page 373
Re: Unplanned Conversion from Partial to Radical Nephrectomy: An Analysis of Incidence, Etiology, and Risk Factors
Steven C. Campbell a,* Worapat Attawettayanon a Carlos Munoz-Lopez a,b Nityam Rathi
doi : 10.1016/j.eururo.2022.12.019
Volume 83, Issue 4, April 2023, Pages 373-374
Small Suspicious Lymph Nodes Detected on Ultrahigh-field Magnetic Resonance Imaging (MRI) in Patients with Prostate Cancer with High Risk of Nodal Metastases: The First In-patient Study on Ultrasmall Superparamagnetic Iron Oxide–enhanced 7T MRI
Ansje Fortuin a,b , Jack van Asten a , Andor Veltien a , Bart Philips a , Thomas Hambrock a , So ̈ren Johst c , Stephan Orzada c,d,e , Boris Hadaschik f,g , Harald Quick c,d , Jelle Barentsz a , Marnix Maas a , Tom Scheenen
doi : 10.1016/j.eururo.2023.01.002
Volume 83, Issue 4, April 2023, Pages 375-377
In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity
Gabriel E. Molina a , Ben Schwartz a , Sandy Srinivas b , Sumit Shah b , Lisa C. Zaba
doi : 10.1016/j.eururo.2022.12.009
Volume 83, Issue 4, April 2023, Pages 377-378
Urethritis Without Skin Lesions as the Primary Manifestation of Mpox Virus Infection
Laurens Liesenborghs a,*, Veerle Huyst a , Christophe Van Dijck a , Jojanneke Rutgers a , Irith De Baetselier a , Chris Kenyon a,b , Marjan Van Esbroeck a , Koen Vercauteren
doi : 10.1016/j.eururo.2022.12.022
Volume 83, Issue 4, April 2023, Pages 378-379
A Transgender Patient with Prostate Cancer: Lessons Learnt
Khobe Chandran a,b , Rafael Grochot a,b , Maria de Los Dolores Fenor De La Maza a,b , Wei Yuan a , Bora Gurel a , Susana Miranda a , Alec Paschalis a,b , Ruth Riisnaes a , Ines Figueiredo a , Denisa Bogdan a , Adam Sharp a,b , Suzanne Carreira a , Johann S. de Bono
doi : 10.1016/j.eururo.2022.12.027
Volume 83, Issue 4, April 2023, Pages 379-380
Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol 2022;82:341–51
Maria Maddalena Sirufo a,b,d Lia Ginaldi a,b,c Massimo De Martinis
doi : 10.1016/j.eururo.2022.12.033
Volume 83, Issue 4, April 2023, Page e102
Re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol. 2023;83:48–54
Sandra GarcÃa Nader * Sebastián Peña RodrÃguez Cesar Alejandro Diaz Ritter
doi : 10.1016/j.eururo.2022.11.027
Volume 83, Issue 4, April 2023, Page e103
Reply to Sandra Patricia GarcÃÂa Nader, Sebastián Peña RodrÃÂguez, and Cesar Alejandro Diaz Ritter’s Letter to the Editor re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol. 2023;83:48–54
Farnoosh Nik-Ahd a,* Matthew R. Cooperberg a Stephen J. Freedland
doi : 10.1016/j.eururo.2022.12.030
Volume 83, Issue 4, April 2023, Page e104
Re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, Jørgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00470
Benjamin Pradere a,b Giuseppe Basile c Thomas Seisen
doi : 10.1016/j.eururo.2022.12.036
Volume 83, Issue 4, April 2023, Pages e105-e106
Reply to Benjamin Pradere, Giuseppe Basile, and Thomas Seisen’s Letter to the Editor re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, Jørgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol 2023;41:2,206–11
Maria S. Lindgren a,* Jørgen B. Jensen
doi : 10.1016/j.eururo.2023.01.015
Volume 83, Issue 4, April 2023, Pages e107-e108
Re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Follow-up Update of PURE-01 Trial. Clin Cancer Res 2022;28:5107–14
Chao Quan a,b Jinbo Chen a,b,* Jiao Hu
doi : 10.1016/j.eururo.2022.12.035
Volume 83, Issue 4, April 2023, Pages e109-e110
Reply to Chao Quan, Jinbo Chen, and Jiao Hu’s Letter to the Editor re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Follow-up Update of PURE-01 Trial. Clin Cancer Res 2022;28:5107–14
Giuseppe Basile a,* Marco Bandini a Francesco Montorsi a Andrea Necchi
doi : 10.1016/j.eururo.2023.01.014
Volume 83, Issue 4, April 2023, Pages e111-e112
Improving Systemic Therapy for Fumarate Hydratase–deficient Renal Cell Carcinoma
Maria I. Carlo
doi : 10.1016/j.eururo.2022.12.020
Volume 83, Issue 4, April 2023, Pages e113-e114
Reply to Jon Griffin. TIME for a Change? Multimarker Assessment of the Tumour Immune Microenvironment and Metastatic Site Biopsy to Improve Immunotherapy Response Prediction in Muscle-invasive Bladder Cancer. Eur Urol. 2023;43:143–4
Niklas Klu ̈mper a,b,c,d , Michael Ho ̈lzel b,c , Markus Eckstein
doi : 10.1016/j.eururo.2023.01.013
Volume 83, Issue 4, April 2023, Pages e115-e116
Corrigendum to “Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial” [Eur Urol 2022;81(6):598–605]
Taimur T. Shah a,b,c,1,*, Abi Kanthabalan c,1, Marjorie Otieno c , Menelaos Pavlou d , Rumana Omar d , Sola Adeleke e,f,g,t,u , Francesco Giganti c,h , Chris Brew-Graves e , Norman R. Williams c , Jack Grierson c , Haroon Miah c , Amr Emara i,v , Athar Haroon j,k , Arash Latifoltojar e,l , Harbir Sidhu e,h , Joey Clemente c , Alex Freeman m , Clement Orczyk c,n , Ashok Nikapota o , Tim Dudderidge p , Richard G. Hindley i , Jaspal Virdi q , Manit Arya b , Heather Payne r , Anita Mitra r , Jamshed Bomanji k , Mathias Winkler a,b , Gail Horan s , Caroline M. Moore c,n , Mark Emberton c,n , Shonit Punwani e,h , Hashim U. Ahmed
doi : 10.1016/j.eururo.2023.01.004
Volume 83, Issue 4, April 2023, Pages e117-e118
Congress Calendar
doi : 10.1016/j.eururo.2023.02.003
Volume 83, Issue 4, April 2023, Pages e119-e120
